Quincy Bioscience Begins Recruitment for Migraine Study

Madison, Wis (Feb 9, 2012) – Quincy Bioscience is pleased to announce that recruitment is underway for a migraine study, evaluating the effectiveness of the jellyfish calcium-binding protein apoaequorin on quality of life for migraine sufferers.

The Online Migraine Trial is a patient-rated outcomes study in which participants complete validated rating scales via the internet over a three month period of time. Migraineurs 18 to 50 years old who experience 3 or more migraines per month are encouraged to apply at www.onlinemigrainetrial.com.

Apoaequorin is a naturally-sourced calcium-binding protein which has proven neuroprotective by its ability to help to regulate intracellular calcium levels. High levels of intracellular calcium are believed to be one cause of the cortical spreading depression associated with migraine headaches.

Migraines are a chronic neurological disease and affect over 30 million adult Americans, with women three times more likely to suffer from recurring migraines.

The study offers migraine sufferers the opportunity to enroll and participate from their own homes. Unlike conventional trials which may require blood draws and clinic visits, the Online Migraine Trial is non-invasive and is convenient to participate.

For more information or to ask a question, visit www.onlinemigrainetrial.org.

Media Contact:
Todd Olson
(608) 827-8134
tolson@quincybioscience.com

About Quincy Bioscience

Quincy Bioscience is a biotechnology company based inMadison,Wisconsin. Quincy Bioscience is focused on the discovery and development of novel compounds to fight the aging process. The company's technology focuses on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.

Tags: